Zacks.com on MSN3h
Gilead, MRK Report Data From Investigational Combination Study for HIVGilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment ...
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following ...
As you can see from the chart above the percentage of shares that are sold short for Gilead Sciences has declined since its ...
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
(Reuters) -Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for patients with a type of ...
Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $84.95 which represents a slight increase of $0.28 or 0.33% from the prior close of $84.67. The stock opened at $84 ...
Shares of Gilead Sciences Inc. GILD inched 0.33% higher to $84.95 Friday, on what proved to be an all-around great trading ...
After falling short in a confirmatory clinical trial, Gilead Sciences has decided to withdraw Trodelvy as a bladder cancer treatment in the U.S. The California biotech announced the decision ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback